Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SANA BIOTECHNOLOGY, INC.

(SANA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
19.81(c) 19.68(c) 19.87(c) 20.8(c) 20.79(c) Last
388 017 552 106 322 183 292 632 322 873 Volume
+0.81% -0.66% +0.97% +4.68% -0.05% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -374 M - -
Net cash position 2021 544 M - -
P/E ratio 2021 -9,87x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -439 M - -
Net cash position 2022 331 M - -
P/E ratio 2022 -8,80x
Yield 2022 -
Capitalization 3 756 M 3 756 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 321
Free-Float 87,8%
More Financials
Company
Sana Biotechnology, Inc is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic... 
More about the company
Ratings of Sana Biotechnology, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about SANA BIOTECHNOLOGY, INC.
10/15ILLUMINA : Appoints Bob Ragusa as GRAIL's CEO
MT
09/17INSIDER SELL : Sana Biotechnology
MT
09/13SANA BIOTECHNOLOGY, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
09/13INSIDER SELL : Sana Biotechnology
MT
09/07Sana Biotechnology to Present at the Morgan Stanley 19th Annual Global Healthcare Confe..
GL
09/07Top Premarket Decliners
MT
09/03SANA BIOTECHNOLOGY, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/03Geoffrey Von Maltzahn to Resign from the Board of Directors of Sana Biotechnology, Inc
CI
08/09SANA BIOTECHNOLOGY : MaxCyte, Sana Biotechnology Enter License Agreement for Cell Engineer..
MT
08/09MAXCYTE : Grants Sana Biotechnology Commercial Rights On Cell-Engineering Tech
MT
08/09SANA BIOTECHNOLOGY : MaxCyte Signs Clinical and Commercial License with Sana Biotechnology
PR
08/06SANA BIOTECHNOLOGY : JPMorgan Adjusts Price Target for Sana Biotechnology to $31 From $35,..
MT
08/06SANA BIOTECHNOLOGY : Goldman Sachs Adjusts Price Target on Sana Biotechnology to $34 From ..
MT
08/04SANA BIOTECHNOLOGY : Reports Second Quarter 2021 Financial Results and Business Updates (F..
PU
08/04SANA : Q2 Earnings Snapshot
AQ
More news
News in other languages on SANA BIOTECHNOLOGY, INC.
10/15Illumina nomme Bob Ragusa au poste de PDG de GRAIL
More news
Analyst Recommendations on SANA BIOTECHNOLOGY, INC.
More recommendations
Chart SANA BIOTECHNOLOGY, INC.
Duration : Period :
Sana Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANA BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 20,79 $
Average target price 37,50 $
Spread / Average Target 80,4%
EPS Revisions
Managers and Directors
Steven D. Harr President, Chief Executive Officer & Director
Nathan Hardy Chief Financial Officer & Senior Vice President
Hans Edgar Bishop Chairman
Sunil Agarwal Chief Medical Officer, EVP & Head-Development
Stacey Ma EVP & Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
SANA BIOTECHNOLOGY, INC.0.00%3 756
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414